Sanctuary Advisors LLC Sells 187,266 Shares of Organon & Co. $OGN

Posted by George Bondi on May 13th, 2026

Sanctuary Advisors LLC reduced its holdings in Organon & Co. (NYSE:OGN – Free Report) by 86.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 29,002 shares of the company’s stock after selling 187,266 shares during the quarter. Sanctuary Advisors LLC’s holdings in Organon & Co. were worth $208,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of OGN. Foster Dykema Cabot & Partners LLC bought a new stake in shares of Organon & Co. during the third quarter worth $29,000. Farther Finance Advisors LLC increased its position in shares of Organon & Co. by 87.8% during the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after acquiring an additional 2,033 shares in the last quarter. Rothschild Investment LLC increased its position in shares of Organon & Co. by 73.1% during the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after acquiring an additional 1,646 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Organon & Co. by 70.2% during the third quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company’s stock worth $53,000 after acquiring an additional 2,109 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Organon & Co. by 50.1% during the fourth quarter. KBC Group NV now owns 10,564 shares of the company’s stock worth $76,000 after acquiring an additional 3,524 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

Shares of OGN opened at $13.32 on Wednesday. The firm has a 50-day moving average of $8.36 and a 200-day moving average of $7.91. Organon & Co. has a one year low of $5.69 and a one year high of $13.44. The company has a market cap of $3.50 billion, a PE ratio of 14.32, a price-to-earnings-growth ratio of 1.23 and a beta of 1.57. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42.

Organon & Co. (NYSE:OGN – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business earned $1.02 EPS. The business’s revenue was down 3.5% on a year-over-year basis. As a group, equities analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Monday, May 11th will be paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, May 11th. Organon & Co.’s payout ratio is currently 8.60%.

Insider Activity at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of Organon & Co. stock in a transaction dated Wednesday, May 6th. The stock was bought at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the purchase, the senior vice president owned 52,851 shares of the company’s stock, valued at $705,560.85. The trade was a 100.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.62% of the company’s stock.

Analyst Upgrades and Downgrades

OGN has been the subject of a number of research reports. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Barclays raised their target price on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. Finally, BNP Paribas Exane reaffirmed a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Four investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Organon & Co. presently has a consensus rating of “Reduce” and a consensus target price of $11.40.

Get Our Latest Research Report on OGN

Organon & Co. Profile

(Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.